384 related articles for article (PubMed ID: 18458230)
1. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Simpson DM; Blitzer A; Brashear A; Comella C; Dubinsky R; Hallett M; Jankovic J; Karp B; Ludlow CL; Miyasaki JM; Naumann M; So Y;
Neurology; 2008 May; 70(19):1699-706. PubMed ID: 18458230
[TBL] [Abstract][Full Text] [Related]
2. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.
Hallett M; Albanese A; Dressler D; Segal KR; Simpson DM; Truong D; Jankovic J
Toxicon; 2013 Jun; 67():94-114. PubMed ID: 23380701
[TBL] [Abstract][Full Text] [Related]
3. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Simpson DM; Gracies JM; Graham HK; Miyasaki JM; Naumann M; Russman B; Simpson LL; So Y;
Neurology; 2008 May; 70(19):1691-8. PubMed ID: 18458229
[TBL] [Abstract][Full Text] [Related]
4. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Naumann M; So Y; Argoff CE; Childers MK; Dykstra DD; Gronseth GS; Jabbari B; Kaufmann HC; Schurch B; Silberstein SD; Simpson DM;
Neurology; 2008 May; 70(19):1707-14. PubMed ID: 18458231
[TBL] [Abstract][Full Text] [Related]
5. Botulinum neurotoxins for the treatment of focal dystonias: Review of rating tools used in clinical trials.
Del Sorbo F; Albanese A
Toxicon; 2015 Dec; 107(Pt A):89-97. PubMed ID: 26365917
[TBL] [Abstract][Full Text] [Related]
6. Botulinum Toxin Treatment of Movement Disorders.
Safarpour Y; Jabbari B
Curr Treat Options Neurol; 2018 Feb; 20(2):4. PubMed ID: 29478149
[TBL] [Abstract][Full Text] [Related]
7. [Movement disorders and botulinum toxin in neurology].
Sangla S; Trocello JM; Bourdain F; Vidal JS; Gallouedec G; Vidailhet M
Ann Readapt Med Phys; 2003 Jul; 46(6):307-11. PubMed ID: 12928135
[TBL] [Abstract][Full Text] [Related]
8. Evidence for the effectiveness of botulinum toxin for writer's cramp.
Dashtipour K; Pender RA
J Neural Transm (Vienna); 2008; 115(4):653-6. PubMed ID: 18322638
[TBL] [Abstract][Full Text] [Related]
9. Botulinum neurotoxin for the treatment of movement disorders.
Kopanidis P; Das C
Aust J Gen Pract; 2018 Sep; 47(9):598-601. PubMed ID: 30244558
[TBL] [Abstract][Full Text] [Related]
10. Botulinum Toxin Treatment of Blepharospasm, Orofacial/Oromandibular Dystonia, and Hemifacial Spasm.
Karp BI; Alter K
Semin Neurol; 2016 Feb; 36(1):84-91. PubMed ID: 26866500
[TBL] [Abstract][Full Text] [Related]
11. Botulinum toxins in the treatment of primary focal dystonias.
Truong D
J Neurol Sci; 2012 May; 316(1-2):9-14. PubMed ID: 22336699
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin in movement disorders.
Papapetropoulos S; Singer C
Semin Neurol; 2007 Apr; 27(2):183-94. PubMed ID: 17390263
[TBL] [Abstract][Full Text] [Related]
13. [Botulinum toxin therapy for focal dystonia].
Hahn K; Niklai E; Garzuly F; Szupera Z
Orv Hetil; 2009 Jul; 150(29):1381-4. PubMed ID: 19581172
[TBL] [Abstract][Full Text] [Related]
14. Update on the Use of Botulinum Toxin Therapy for Focal and Task-Specific Dystonias.
Lungu C; Ahmad OF
Semin Neurol; 2016 Feb; 36(1):41-6. PubMed ID: 26866495
[TBL] [Abstract][Full Text] [Related]
15. Botulinum neurotoxin a therapy efficacy and safety for oromandibular dystonia: a meta-analysis.
Dadgardoust PD; Rosales RL; Asuncion RM; Dressler D
J Neural Transm (Vienna); 2019 Feb; 126(2):141-148. PubMed ID: 30604200
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Blepharospasm and Oromandibular Dystonia with Botulinum Toxins.
Hassell TJW; Charles D
Toxins (Basel); 2020 Apr; 12(4):. PubMed ID: 32331272
[TBL] [Abstract][Full Text] [Related]
17. International consensus statement for the use of botulinum toxin treatment in adults and children with neurological impairments--introduction.
Esquenazi A; Novak I; Sheean G; Singer BJ; Ward AB
Eur J Neurol; 2010 Aug; 17 Suppl 2():1-8. PubMed ID: 20633176
[TBL] [Abstract][Full Text] [Related]
18. [Botulinum toxin for treatment of the focal dystonia].
Nakamura Y
Rinsho Shinkeigaku; 2017 Jul; 57(7):367-372. PubMed ID: 28652522
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic and therapeutic recommendations in adult dystonia: a joint document by the Italian Society of Neurology, the Italian Academy for the Study of Parkinson's Disease and Movement Disorders, and the Italian Network on Botulinum Toxin.
Romano M; Bagnato S; Altavista MC; Avanzino L; Belvisi D; Bologna M; Bono F; Carecchio M; Castagna A; Ceravolo R; Conte A; Cosentino G; Eleopra R; Ercoli T; Esposito M; Fabbrini G; Ferrazzano G; Lalli S; Mascia MM; Osio M; Pellicciari R; Petrucci S; Valente EM; Valentino F; Zappia M; Zibetti M; Girlanda P; Tinazzi M; Defazio G; Berardelli A
Neurol Sci; 2022 Dec; 43(12):6929-6945. PubMed ID: 36190683
[TBL] [Abstract][Full Text] [Related]
20. Treatment of focal dystonias with botulinum neurotoxin.
Hallett M; Benecke R; Blitzer A; Comella CL
Toxicon; 2009 Oct; 54(5):628-33. PubMed ID: 19103214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
